KAS
LPCN icon

Kestra Advisory Services’s Lipocine LPCN Stock Holding History

Kestra Advisory Services’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,703
Closed -$49.8K – 2309
2023
Q3 		$49.8K Hold
16,703
– – ﹤0.01% 2053
2023
Q2 		$84.2K Buy
16,703
+2
+0% +$9 ﹤0.01% 2015
2023
Q1 		$90.3K Hold
16,701
– – ﹤0.01% 1964
2022
Q4 		$113K Buy
16,701
+448
+3% +$3.27K ﹤0.01% 2128
2022
Q3 		$124K Buy
16,253
+88
+0.5% +$983 ﹤0.01% 1953
2022
Q2 		$220K Sell
16,165
-1,911
-11% -$29.8K ﹤0.01% 1844
2022
Q1 		$421K Buy
18,076
+3,941
+28% +$82.5K ﹤0.01% 1388
2021
Q4 		$238K Sell
14,135
-537
-4% -$9.97K ﹤0.01% 1767
2021
Q3 		$272K Buy
14,672
+10,554
+256% +$233K ﹤0.01% 1751
2021
Q2 		$98K Buy
+4,118
New +$96.8K ﹤0.01% 1953
2021
Q1 		– Sell
-20,360
Closed -$453K – 1963
2020
Q4 		$453K Buy
+20,360
New +$490K 0.01% 1256

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kestra Advisory Services's LPCN Position: Q4 2023 in Review

Kestra Advisory Services sold out of Lipocine (LPCN) in Q4 2023, closing a stake of 16,703 shares — an estimated $49.8K sold.

Kestra Advisory Services first reported a position in LPCN in Q4 2020 and held it in 11 quarters. The position peaked at $453K in Q4 2020. 19 funds tracked by Wall St. Rank hold LPCN as of Q4 2023.

  • Kestra Advisory Services reported no remaining Lipocine position as of Q4 2023 after selling out during the quarter.
  • Kestra Advisory Services sold 16,703 Lipocine shares in Q4 2023, an estimated $49.8K.
  • Kestra Advisory Services first reported a position in Lipocine in Q4 2020 and held it in 11 quarters.
  • Kestra Advisory Services's Lipocine position peaked at $453K in Q4 2020.
  • 19 funds tracked by Wall St. Rank held Lipocine as of Q4 2023.

Based on Kestra Advisory Services's 13F filing for Q4 2023, filed 14 Feb 2024.